Capehorn, Matthew
The Rotherham NHS Foundation Trust
4 papers on CoChatORCID 0000-0002-8196-2505
Most cited papers
- Verified
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 596
- Verified
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 412
- Verified
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology
Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases
Cited by 91
- Verified
SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS
Rosenstock, J., Capehorn, M., De Remigis, A., Rasmussen, S., Weimers, P., & Mosenzon, O. (2021) · Journal of the American College of Cardiology
Diabetes Treatment and ManagementLipoproteins and Cardiovascular Health
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free